TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Message from the CEO to MediciNova Shareholders

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Yuichi Iwaki, M.D., Ph.D.
Message from the CEO to MediciNova Shareholders

MediciNova published research demonstrating how its drug MN-001 potentially improves cholesterol transport and addresses metabolic disorders, with Phase 2 trial results expected in summer 2026.

Insights
MNOV   positive

Company reported promising research findings, completed patient enrollment in Phase 2 trial, and demonstrated potential for novel therapeutic approach in treating metabolic and cardiovascular diseases